Laboratory Productivity Improves with First Commercial Mass Spectrometry-based System for Amino Acid Analysis.

Amino Acid 20/20 Analyzer from Applied Biosystems/MDS SCIEX Brings New Approach to Common Pharmaceutical, Food Testing, and Protein Research Applications

FOSTER CITY, Calif. -- Applied Biosystems (NYSE: ABI), an Applera Corporation business, and its joint venture partner, MDS Sciex, a division of MDS Inc. (NYSE:MDZ, TSX:MDS), today announced a new laboratory system that uses mass spectrometry to reliably, cost-effectively and efficiently perform amino acid analysis. The new Amino Acid 20/20TM Analyzer is designed to increase productivity of laboratory researchers by improving the effectiveness and reliability of applications that are commonly used to conduct amino acid analysis. The new system is the first to combine mass spectrometry with unique tagging reagents for use with these applications.

Amino acids, which are the building blocks of proteins, are analyzed to measure and characterize proteins. This process is utilized in a variety of applications that include biopharmaceutical quality control and assessment of the nutritional value of foods, beverages and animal feed.

Amino acid analysis is typically performed using a well-established technology called chromatography, which dates back to the 1950s. And while a proven technology, the chromatography-based process is known by the research community to be rather laborious and prone to breakdowns. The Amino Acid 20/20TM Analyzer is a significant step forward with more than twice the speed of existing chromatography systems. The new system also provides better separation of amino acids, including difficult-to-distinguish isobaric amino acids, which have identical masses. Moreover, the internal standards established by the tagging reagents ensure the accuracy of quantitation.

Biopharmaceutical companies conduct amino acid analysis as standard practice for purposes such as quality control and optimizing biology discovery lab applications. One of the first pharmaceutical companies to utilize the Amino Acid 20/20TM Analyzer is GlaxoSmithKline, one of the world's largest over-the-counter consumer healthcare products companies. "We are already realizing a significant time and cost savings with the speed, sensitivity and reliability of the Amino Acid 20/20TM Analyzer in our lab," said Jon Williams, manager, discovery research, GlaxoSmithKline. "The higher sensitivity also allows us to use less sample, which in some cases is quite precious."

Another industry in which amino acid analysis plays an important role is renewable fuel production. A research center focused on improving the benefits of fuel ethanol production in the expanding biofuel industry is the National Corn to Ethanol Research Center, located in Illinois. By performing amino acid analysis, the center determines the nutritional value of the co-product used for animal feed. "The nutritional yield determines market value of the product," explained Yanhong Zhang, Ph.D, Analytical Lab Manager. "With its reliable, simple operation, even non-technical users can use the Amino Acid 20/20TM Analyzer to confirm the amino acid composition, thereby improving the marketability and economics of the corn-to-ethanol process."

The Amino Acid 20/20TM Analyzer is based on the high-performance Applied Biosystems/MDS SCIEX triple quadrupole mass spectrometers and uses proprietary chemistry reagents called Applied Biosystems iTRAQ[TM] reagents, which provide a unique way to label the amino acids that are subsequently analyzed for accurate quantitation. The new system also incorporated the new Cliquid[TM] applications software; which was designed to make mass spectrometry-based applications easier to use.

"As the first mass spectrometry-based system to meet significant unmet needs of the amino acid analysis market - namely, higher throughput and accurate quantitation of key amino acids - this system extends Applied Biosystems/MDS SCIEX's innovative technologies for additional use in pharmaceutical companies, food testing facilities and research centers," said Laura Lauman, division president, Proteomics & Small Molecule Division, Applied Biosystems.

Andy Boorn, president of MDS Sciex, concluded that, "The Amino Acid 20/20TM Analyzer is a reliable and powerful tool for the researchers in biopharmaceutical quality control and nutritional testing. The combination of our robust and high performance mass spectrometers with the easy-to-use software will bring greater accuracy and speed to their testing."

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of over $1.9 billion during fiscal 2006. The Celera Genomics Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers. Celera Genomics maintains a strategic alliance with Abbott Laboratories for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera Genomics is also discovering and validating therapeutic targets, and it is seeking strategic partnerships to develop therapeutic products based on these discovered targets. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.

About MDS Sciex and MDS Inc.

MDS Sciex is the scientific instrumentation and technology solutions division of MDS Inc. MDS Inc. (TSX:MDS)(NYSE:MDZ) has more than 8,800 highly skilled people in 27 countries. It provides a diverse range of superior products and services to increase customers' speed, precision and productivity in the drug development and disease diagnosis processes. MDS is a global, values-driven life sciences company, recognized for its reliability and collaborative relationships that help create better outcomes in the treatment of disease. Find out more at www.mdsinc.com or by calling 1-800-MDS-7222, 24 hours a day.

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "should," "expect," and "planned," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; and (3) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Applied Biosystems, AB (design), Applera and Celera are registered trademarks and iTRAQ is a trademark of Applera Corporation or its subsidiaries in the US and/or certain other countries. Cliquid is a trademark of Applied Biosystems/MDS SCIEX, a joint venture between Applera Corporation and MDS Inc. Copyright[c] 2006. Applera Corporation and MDS Inc. All rights reserved.